Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.

Antonio CanoRossella E NappiNanette SantoroPetra StuteMartin BloggMarci L EnglishAntonia MorgaLudmila ScrineEmad SiddiquiFaith D Ottery

Published in: BJOG : an international journal of obstetrics and gynaecology (2024)

Fezolinetant treatment was associated with improvement in overall QoL, measured by MENQoL, and work productivity, measured by WPAI-VMS. A high proportion receiving fezolinetant felt VMS were 'much better' based on PGI-C VMS responder analysis.

Keyphrases

climate change
electronic health record
postmenopausal women
clinical trial
sleep quality
depressive symptoms
replacement therapy
artificial intelligence